These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 26109728

  • 21. Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.
    Cardozo T, Wang S, Jiang X, Kong XP, Hioe C, Krachmarov C.
    Vaccine; 2014 Sep 03; 32(39):4916-24. PubMed ID: 25045827
    [Abstract] [Full Text] [Related]

  • 22. Thermodynamic signatures of the antigen binding site of mAb 447-52D targeting the third variable region of HIV-1 gp120.
    Killikelly A, Zhang HT, Spurrier B, Williams C, Gorny MK, Zolla-Pazner S, Kong XP.
    Biochemistry; 2013 Sep 10; 52(36):6249-57. PubMed ID: 23944979
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
    Laman JD, Schellekens MM, Abacioglu YH, Lewis GK, Tersmette M, Fouchier RA, Langedijk JP, Claassen E, Boersma WJ.
    J Virol; 1992 Mar 10; 66(3):1823-31. PubMed ID: 1637373
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Epitope mapping, V-region DNA sequence, and neutralizing Fab fragments of two monoclonal antibodies against the HIV-1 V3 loop.
    Duarte CA, Pérez L, Vázquez J, Dueñas M, Vilarrubia OL, Navea L, Valdés R, Reyes O, Montero M, Ayala M, Gavilondo J.
    Immunotechnology; 1996 Feb 10; 2(1):11-20. PubMed ID: 9373324
    [Abstract] [Full Text] [Related]

  • 29. Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells.
    Rao PG, Lambert GS, Upadhyay C.
    J Virol; 2023 Sep 28; 97(9):e0071023. PubMed ID: 37681958
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.
    Longo NS, Sutton MS, Shiakolas AR, Guenaga J, Jarosinski MC, Georgiev IS, McKee K, Bailer RT, Louder MK, O'Dell S, Connors M, Wyatt RT, Mascola JR, Doria-Rose NA.
    J Virol; 2016 Dec 01; 90(23):10574-10586. PubMed ID: 27654288
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
    Ching LK, Vlachogiannis G, Bosch KA, Stamatatos L.
    J Virol; 2008 Jan 01; 82(2):949-56. PubMed ID: 18003732
    [Abstract] [Full Text] [Related]

  • 35. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y, Man L, Qiu Z, Yang L, Sun Y, He Y.
    Antiviral Res; 2016 Aug 01; 132():252-61. PubMed ID: 27387828
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.